Development of a near-care diagnostic test for Lyme disease

莱姆病近护理诊断测试的开发

• 批准号: 549597-2020
• 负责人: Frampton, John
• 金额: $ 10.47万
• 依托单位: Dalhousie University
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=722582
• 关键词: Development; near; care; diagnostic; test

Lyme disease is the most common tick-borne illness in North America. New cases of Lymedisease are on the rise throughout Canada, which has prompted increased awareness of thedisease and raised issues with the currently available tests used for diagnosis. The currenttests rely on detection of antibodies found in the patients blood that are produced in responseto bacteria that cause Lyme disease. Because these antibody responses develop over timeand vary with degree of infection, the test can be problematic for diagnosing early infection,which may delay antibiotic therapy. Recently, there has been a push to identify additionalnon-antibody Lyme disease markers for use in diagnosis. This research will use a sensitiveand powerful protein discovery approach to mine blood samples for new markers of Lymedisease. The proteins identified will be used to develop an improved test for detecting Lymedisease.

莱姆病是北美最常见的扁虱传播疾病。加拿大各地的莱梅病新病例正在上升，这促使人们对这种疾病的认识有所提高，并引发了目前用于诊断的检测方法的问题。目前的检测依赖于对患者血液中发现的抗体的检测，这些抗体是对导致莱姆病的细菌产生的。由于这些抗体反应会随着时间的推移而发展，并随感染程度的不同而变化，因此该检测在诊断早期感染方面可能存在问题，这可能会推迟抗生素治疗。最近，人们一直在努力寻找用于诊断的额外的非抗体莱姆病标志物。这项研究将使用一种灵敏而强大的蛋白质发现方法来挖掘血液样本，以寻找利梅病的新标记物。识别出的蛋白质将被用来开发一种检测莱姆病的改进测试。